Metrics as of 10/17/2026, 06:14 AM (Berlin time), refresh in progress.
Lantheus Holdings Stock
Lantheus Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Mary Anne Heino
- Employees
- 1,193
- Market cap
- $6.5 B
- IPO
- 25/06/2015
Lantheus Holdings, Inc. operates in the Healthcare / Drug Manufacturers - Specialty & Generic sector and specializes in the development and commercialization of advanced diagnostics and therapeutics. Headquartered in North Billerica, Massachusetts, the U.S. company focuses its products primarily on cardiac diagnostics…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Lantheus Holdings stock: price history
1D
-0.3%
1W
-0.4%
1M
-0.8%
6M
+18.9%
YTD
+49.8%
1Y
+76.9%
2Y
-11.4%
5Y
+328.6%
10Y
+1,194.8%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~70% stronger price swings than usual
Lantheus Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
2 more assignments (Enabler/Second row) Pro-only.
Lantheus Holdings operates a business model in the specialized pharmaceutical and diagnostics sector. The company develops, manufactures, and distributes advanced diagnostic and therapeutic agents for the examination and treatment of cancer and cardiovascular disease. A key component of its portfolio comprises radiopharmaceuticals such as PYLARIFY and therapeutics such as AZEDRA. Additionally, the offering includes software-based solutions for medical image analysis. Revenue is generated primarily through the sale of these specialized pharmaceutical products, with licensing fees also playing a role. The company operates in a highly specialized market with a broad customer base comprising hospitals and pharmacies.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Low
Suppliers & customers in our universe
Bausch Health Companies Inc.DescriptionAsk the agents about Lantheus Holdings
Analyst assessment of Lantheus Holdings
PRICE TARGET LOW
US$94.00
CONSENSUS
US$102.65
MEDIAN
US$102.50
PRICE TARGET HIGH
US$109.00
0
STRONG BUY
10
BUY
9
HOLD
0
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 13/10/2026
Lantheus Holdings stock metrics
P/E
23.68
P/B
4.95
EV/EBITDA
13.88
RETURN ON EQUITY
5.7%
NET MARGIN
19.3%
DEBT/EQUITY
0.48
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
89.8%
FLOAT SHARES
58,613,282
AVG. DAILY VOLUME (30D)
989,603
Insider transactions (SEC)
Lantheus Alpha Therapy, LLC
Lantheus Alpha Therapy, LLC
Lantheus Alpha Therapy, LLC
Lantheus Holdings, Inc.
Marshall Robert J. Jr.
Attention
Price since yesterday: -0.3%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Lantheus Holdings stock
What does Lantheus Holdings do?
Lantheus Holdings, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Mary Anne Heino, the company employs around 1,193 people.
The IPO was on 25/06/2015; the stock trades on NASDAQ under the ticker LNTH.
What do analysts say about Lantheus Holdings stock?
19 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$102.65, ranging from US$94.00 to US$109.00, with a median of US$102.50.
This is an external assessment, not a statement by Market Jury.
When does Lantheus Holdings report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 70% stronger than usual.
Does Lantheus Holdings pay a dividend?
No, Lantheus Holdings currently does not pay a dividend.
Which stocks are comparable to Lantheus Holdings?
Comparable stocks include Zoetis, Viatris, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences, Amphastar Pharmaceuticals and Aquestive Therapeutics.
How can I get Lantheus Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lantheus Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.